New progress in the diagnosis of childhood tuberculosis

doi:10.3969/j.issn.1000-6621.2018.04.013

Abstract

Abstract:

Childhood tuberculosis is widespread, the morbidity and mortality are both high. WHO reported that the number of childhood tuberculosis have reached to 1 million all over the world, and the number of deaths have reached 140 thousand in 2016. In order to control the prevalence of childhood tuberculosis, WHO put forward a blueprint of “towards zero death for childhood tuberculosis”. However, childhood tuberculosis is without typical symptoms, and it is difficult to obtain specimens.Furthermore, the bacterial rate of Mycobacterium tuberculosis is low and diagnose of childhood tuberculosis is still very difficult. Therefore, zero death is still a huge challenge. It is very necessary to detect the best diagnostic method and improve the early diagnosis rate of childhood tuberculosis. This review is just of the latest diagnostic technology and procedures of childhood tuberculosis.

Key words: Pediatrics, Tuberculosis, Diagnosis,differential, Diagnostic techniques and procedures, Review

Lu XIA,Yao ZHANG,Shui-hua LU. New progress in the diagnosis of childhood tuberculosis[J]. Chinese Journal of Antituberculosis, 2018, 40(4): 416-419. doi: 10.3969/j.issn.1000-6621.2018.04.013

References 30

[1]	World Health Organization . Global tuberculosis report 2016. Geneva:World Health Organization, 2016.
[2]	Dodd PJ, Yuen CM, Sismanidis C , et al. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health, 2017,5(9):e898-906. doi: 10.1016/S2214-109X(17)30289-9 URL pmid: 5556253
[3]	全国结核病流行病学抽样调查技术指导组, 全国流行病学抽样调查办公室. 第四次全国结核病流行病学抽样调查报告. 中华结核和呼吸杂志, 2002,25(1):3-7. doi: 10.3760/j:issn:1001-0939.2002.01.002 URL
[4]	WHO Guidelines Approved by the Guidelines Review Committee. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva: World Health Organization, 2014.
[5]	World Health Organization. Childhood TB training toolkit. Geneva:World Health Organization, 2014.
[6]	World Health Organization. Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle- Income Countries: Policy Statement. Geneva: World Health Organization, 2011.
[7]	李锋, 卢水华 . γ干扰素释放试验在儿童结核病和潜伏结核感染中的诊断价值. 中国防痨杂志, 2015,37(7):732-735. doi: 10.3969/j.issn.1000-6621.2015.07.004 URL
[8]	Shimizu H, Mori M . Usefulness of the Combination of Tuberculin Skin Test and Interferon-Gamma Release Assay in Diagnosing Children with Tuberculosis. Tohoku J Exp Med, 2017,243(3):205-210. doi: 10.1620/tjem.243.205 URL
[9]	孙琳, 田建岭, 尹青琴 , 等. γ干扰素释放试验在不同年龄活动性结核病患儿诊断中的应用价值. 中国防痨杂志, 2015,37(7):757-763. doi: 10.3969/j.issn.1000-6621.2015.07.009 URL
[10]	Bielecka T, Komorowska-Piotrowska A, Krenke K , et al. Is secretion of IFN-gamma in response to Mycobacterium tuberculosis antigens in youngest children sufficient to play a role in TB diagnostics. Pediatr Pulmonol, 2018,53(2):181-188. doi: 10.1002/ppul.v53.2 URL
[11]	Lombardi G, Petrucci R, Corsini I , et al. Quantitative analysis of interferon-γ release assay response in children with latent and active tuberculosis. J Clin Microbiol, 2018,56(2):e01360.
[12]	Sollai S, Galli L, de Martino M , et al. Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update. BMC Infect Dis, 2014,14:S6.
[13]	Boehme CC, Nabeta P, Hillemann D , et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med, 2010,363(11):1005-1015. doi: 10.1056/NEJMoa0907847 URL
[14]	Detjen AK, DiNardo AR,Leyden J , et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med, 2015,3(6):451-461. doi: 10.5588/ijtld.15.0824 URL pmid: 27155190
[15]	Nhu NT, Ha DT, Anh ND , et al. Evaluation of Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis. BMC Infect Dis, 2013,13:31. doi: 10.1186/1471-2334-13-31 URL pmid: 3562258
[16]	Yin QQ, Jiao WW, Han R , et al. Rapid diagnosis of childhood pulmonary tuberculosis by Xpert MTB/RIF assay using bronchoalveolar lavage fluid. Biomed Res Int, 2014,2014:310194.
[17]	Held M, Laubscher M, Mears S , et al. Diagnostic Accuracy of the Xpert MTB/RIF Assay for Extrapulmonary Tuberculosis in Children With Musculoskeletal Infections. Pediatr Infect Dis J, 2016,35(11):1165-1168. doi: 10.1097/INF.0000000000001271 URL
[18]	Bunyasi EW, Tameris M, Geldenhuys H , et al. Evaluation of Xpert ^® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial . PLoS One, 2015,10(11):e0141623. doi: 10.1371/journal.pone.0141623 URL
[19]	Singh S, Singh A, Prajapati S , et al. Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis. BMC Microbiol, 2015,15:191. doi: 10.1186/s12866-015-0528-z URL
[20]	Banada PP, Naidoo U, Deshpande S , et al. A Novel Sample Processing Method for Rapid Detection of Tuberculosis in the Stool of Pediatric Patients using the Xpert MTB/RIF assay. PLoS One, 2016,11(3):e0151980. doi: 10.1371/journal.pone.0151980 URL
[21]	Chisti MJ, Graham SM, Duke T , et al. A prospective study of the prevalence of tuberculosis and bacteraemia in Bangladeshi children with severe malnutrition and pneumonia including an evaluation of Xpert MTB/RIF assay. PLoS One, 2014,9(4):e93776. doi: 10.1371/journal.pone.0093776 URL
[22]	Dorman SE, Schumacher SG, Alland D , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis, 2018,18(1):76-84. doi: 10.1016/S1473-3099(17)30691-6 URL
[23]	Ruhwald M, Aggerbeck H, Gallardo RV , et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med, 2017,5(4):259-268. doi: 10.1016/S2213-2600(16)30436-2 URL
[24]	Slogotskaya L, Litvinov V, Kochetkov Y , et al. New skin test with recombinant protein CFP10-ESAT6 in patients (children and adults) with tuberculosis, non-tuberculosis disease and latent TB infection. European Respiratory Journal, 2012.
[25]	Li F, Xu M, Qin C , et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016,22(10):889.
[26]	Li F, Xu M, Zhou L , et al. Safety of recombinant fusion protein ESAT6-CFP10 as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, single-center phase I clinical trial. Clin Vaccine Immunol, 2016,23(9):767-773. doi: 10.1128/CVI.00154-16 URL
[27]	World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization, 2006. URL pmid: 17131777
[28]	Mulenga H, Tameris MD, Luabeya KK , et al. The Role of Clinical Symptoms in the Diagnosis of Intrathoracic tuberculosis in Young Children. Pediatr Infect Dis J, 2015,34(11):1157-1162. doi: 10.1097/INF.0000000000000847 URL pmid: 080
[29]	Triasih R, Robertson CF, Duke T , et al. A prospective evaluation of the symptom-based screening approach to the management of children that are contacts of tuberculosis cases. Clin Infect Dis, 2015,60(1):12-18. doi: 10.1093/cid/ciu748 URL
[30]	Kumar MK, Kumar P, Singh A . Recent advances in the diagnosis and treatment of childhood tuberculosis. J Nat Sci Biol Med, 2015,6(2):314-320. doi: 10.7499/j.issn.1008-8830.2014.02.027 URL pmid: 24568924